Comparing the current results to its competitors, Cvrx Inc reported Revenue increase in the 1 quarter 2026 by 12.74 % year on year. The sales growth was above Cvrx Inc 's competitors' average revenue growth of 4.13 %, achieved in the same quarter.
Cvrx Inc 's Comment on Competition and Industry Peers
The company operates in the heart failure with reduced ejection fraction (HFrEF) treatment market, competing based on product safety, clinical data quality, stakeholder adoption, reimbursement, ease of use, sales force capabilities, product support, manufacturing, innovation, and intellectual property. Its device is intended for use alongside pharmaceutical therapies for HFrEF and is not positioned as a direct competitor to these treatments. The company also competes with other medical technology firms to recruit and retain qualified personnel. It holds numerous patents and trademarks to protect its intellectual property and relies on trade secrets and technological innovation to maintain its competitive position. There is no active litigation concerning its patents or intellectual property rights.
August 2, 2024
In a significant development for the cardiovascular medical device landscape, CVRx, Inc. (NASDAQ: CVRX) announced on August 2, 2024, that the Centers for Medicare and Medicaid Services (CMS) has redefined payment parameters for the Barostim implant procedure, marking a crucial milestone for hospital reimbursement under the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Prospective Payment System (IPPS). This adjustment represents a pivotal step in the push toward expanding access to innovative heart failure treatments.The Barostim system, designed for patients suffering from heart failure, targets the autonomic nervous system to improve heart function and quality of life. Previous reimbursement levels had...
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Baxter International Inc is a global healthcare company that specializes in providing a wide range of medical products and services. They operate through various business segments including Pharmaceuticals, Medical Products, and Renal Care, offering solutions for hospitals, clinics, and home-based healthcare settings.
Atricure Inc is a medical device company that focuses on developing, manufacturing, and selling innovative surgical solutions for the treatment of cardiac arrhythmias and other heart-related conditions.
Sources:
Cvrx inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cvrx inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
